Related Experiment Video
Updated: Oct 5, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran in cardiovascular disease management: A comprehensive review
Ayesha Javed1, Muhammad Ajmal2, Aaron Wolfson3
1Department of Internal Medicine, University of Arizona, Tucson, AZ 85719, United States.
Insights
Dabigatran, a direct thrombin inhibitor, is effective for treating blood clots and preventing strokes in specific patient groups. Ongoing research explores its use in diverse cardiovascular conditions, expanding its therapeutic potential.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Dabigatran is a direct thrombin inhibitor with established efficacy.
- Approved indications include deep venous thrombosis, pulmonary embolism, stroke prevention in atrial fibrillation, and VTE prophylaxis post-orthopedic surgery.
Purpose of the Study:
- To provide a comprehensive review of dabigatran's role in cardiovascular diseases.
- To evaluate the safety and efficacy of dabigatran in emerging and less-studied conditions.
Main Methods:
- Literature review of clinical studies and trials.
- Analysis of safety and efficacy data for dabigatran in various cardiovascular settings.
Main Results:
- Robust data supports dabigatran for established indications.
- Emerging research investigates its utility in VTE with malignancy, coronary artery disease, valvular heart disease, and antiphospholipid syndrome.
Conclusions:
- Dabigatran demonstrates significant clinical utility in approved cardiovascular indications.
- Further research is warranted to define its role in complex cardiovascular conditions.
Abstract:
Dabigatran, a direct thrombin inhibitor, has robust data for the treatment of deep venous thrombosis and pulmonary embolism, stroke prevention in non-valvular atrial fibrillation, and the prophylaxis of venous thromboembolism (VTE) after knee and hip replacement. Recent studies have evaluated dabigatran to determine its safety and efficacy in such conditions as VTE in malignancy, coronary artery disease, mechanical and bioprosthetic valves, and antiphospholipid syndrome. This article provides a comprehensive review on the role of dabigatran in various cardiovascular diseases.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

